Overview Request Sample Pages Request Customization Download PDF
You are viewing: France Veterinary Biologics Market analysis
Part of: Veterinary Biologics Market (Global)

The France Veterinary Biologics Market was valued at $71.19 Million in 2025 and projected to reach to $95.48 Million by 2030, representing a compound annual growth rate of CAGR 6.0%. France's veterinary biologics market is positioned for sustained growth through 2030, driven by increasing investments in animal health innovation and compliance with stringent European regulatory frameworks.

France Veterinary Biologics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Veterinary Biologics Market Trends and Insights

  • This growth trajectory reflects France's strong commitment to animal health innovation and regulatory standards within the European veterinary sector.
  • France's market expansion is driven by increasing demand for preventive healthcare solutions, rising pet ownership, and livestock disease management across the country. The French veterinary biologics sector benefits from robust infrastructure, advanced research capabilities, and stringent quality controls that align with European Union directives.
  • France's position as a leading agricultural nation supports sustained demand for biologics in both companion and production animal segments.
  • Between 2025 and 2030, France is anticipated to experience accelerated adoption of immunological products, vaccines, and therapeutic biologics, supported by growing awareness among veterinarians and animal owners regarding disease prevention and animal welfare standards..

Key Market Statistics

  • CAGR (2025-2030) CAGR 6.0%
  • Market Size, 2025 ~USD 71.19 Million
  • Forecast, 2030 ~USD 95.48 Million
  • Country France

France Veterinary Biologics Market Overview

Market Valuation :

France's veterinary biologics market is valued at USD 71.19 million in 2025, with projections reaching USD 95.48 million by 2030, demonstrating robust growth potential in the European veterinary sector.

Strong CAGR Performance :

France's market is growing at a CAGR of 6.0%, outpacing the global average of 5.2%, indicating accelerated adoption of veterinary biologics within the country's animal health ecosystem.

Regulatory Excellence :

France maintains stringent regulatory standards aligned with EU directives, fostering innovation and market confidence in veterinary biologics products, particularly for livestock and companion animals.

European Leadership Position :

As a key European market, France drives demand for advanced immunological products, vaccines, and biologics, supported by strong agricultural and companion animal sectors.

France Veterinary Biologics Market Dynamics

  • The country's robust agricultural sector, combined with rising companion animal ownership, creates consistent demand for advanced biological products including vaccines, immunotherapies, and diagnostic biologics.
  • French veterinary practitioners and livestock producers are increasingly adopting cutting-edge biologics to enhance animal welfare and productivity.
  • Government support for sustainable farming practices and animal disease prevention further accelerates market expansion.
  • The market benefits from France's strong pharmaceutical infrastructure and research capabilities, enabling local and international manufacturers to develop and commercialize innovative veterinary biologics tailored to European standards and consumer preferences..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • France's veterinary biologics market is projected to grow from USD 71.19 million (2025) to USD 95.48 million (2030) at a 6.0% CAGR.
    • France's strong agricultural sector and high pet ownership rates drive consistent demand for preventive biologics and vaccines.
    • France benefits from EU regulatory harmonization, enabling streamlined market access and standardized quality assurance for veterinary biologics.
    • France's market growth is supported by increasing investment in animal health R&D and rising awareness of disease prevention among French veterinarians and livestock producers.

    Veterinary Biologics Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CANINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.2% from 2025 to 2030
    Largest Segment INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 2.72 (2025)
    Revenue Forecast (Billions) ~USD 3.51 (2030)
    Segments Covered Product Type, Animal Type, Type, Route Of Administration, Application, End User

    France Veterinary Biologics Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Product Type

    • Diagnostic Kits
    • Immunodmodulators & Immunostimulants
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Immuoglobulins & Antitoxins
    • Monoclonal Anitbodies
    • Monoclonal Antibodies

    By Animal Type

    • Companion Animal
    • Companion Animals
    • Livestock Animal
    • Livestock Animals

    By Type

    • Bovine
    • Canine
    • Equine
    • Feline
    • Intramuscular Route Of Administration
    • Intravenous Route Of Administration
    • Other Injectable Route Of Administration
    • Porcine
    • Poultry
    • Small Ruminant
    • Subcutaneous Route Of Administration

    By Route Of Administration

    • Injectable Route Of Administration
    • Oral Route Of Administration
    • Other Routes Of Administration

    By Application

    • Dermatology
    • Diagnostic Testing
    • Diagnostic Tetsing
    • Infectious Disease Prevention
    • Oncology
    • Other Applications
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Diagnostic Labs
    • Veterinary Hospitals & Clinics

    FRANCE: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    OTHER END USERS4.824.955.15.265.445.645.876.113.7
    VETERINARY DIAGNOSTIC LABS28.8929.8830.9832.2233.5735.0836.7738.594.5
    VETERINARY HOSPITALS & CLINICS79.1283.1287.5292.4397.81103.79110.5117.756.1
    TOTAL112.84117.96123.6129.9136.81144.51153.14162.455.6

    Target Audience

    • Veterinary Biologics Manufacturers : Manufacturers need France-specific market data to assess market size, growth potential, and competitive positioning for product launches, licensing agreements, and regional expansion strategies.
    • Pharmaceutical & Biotech Companies : Companies seeking European market entry require detailed France insights to evaluate market viability, regulatory pathways, and revenue forecasts for veterinary biologics portfolios.
    • Investment & Private Equity Firms : Investors need France market analysis to identify growth opportunities, assess portfolio company performance, and make informed decisions on veterinary health sector investments.
    • Veterinary Distributors & Retailers : Distributors require France market forecasts to optimize inventory management, negotiate supplier contracts, and align product offerings with regional demand trends.
    • Government & Regulatory Bodies : French agricultural and health authorities need market intelligence to develop animal health policies, support domestic industry competitiveness, and ensure public health preparedness.

    Key Companies in the France Veterinary Biologics Market

    CompanyHQOwnershipStrongest segments
    IDEXXUnited StatesPublic CompanyCompanion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics),
    ELANCOUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others),
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    NEOGEN CORPORATIONUnited StatesPublic CompanyFood Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables,
    IMMUCELL CORPORATIONUnited StatesPublic CompanyFirst Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations,

    IDEXX

    IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.

    ELANCO

    Elanco is a public company founded in 1954 in the United States with 9,650 employees.

    MERCK & CO., INC.

    Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.

    NEOGEN CORPORATION

    Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.

    IMMUCELL CORPORATION

    ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.

    Reasons to Buy this Report

    • Precise Market Sizing : Access validated market valuations specific to France (USD 71.19M in 2025), enabling accurate budgeting and investment decisions for veterinary biologics expansion in the French market.
    • Growth Trajectory Insights : Understand France's 6.0% CAGR performance versus global 5.2%, identifying outperformance drivers and opportunities for market penetration in this high-growth European segment.
    • Regulatory & Compliance Framework : Gain detailed insights into France's EU-aligned regulatory environment, helping manufacturers navigate approval processes and ensure product compliance for successful market entry.
    • Competitive Landscape Analysis : Benchmark against France-specific market dynamics, competitor strategies, and local demand patterns to optimize product positioning and capture market share effectively.
    • Strategic Planning Support : Leverage France-focused forecasts through 2030 to develop long-term business strategies, resource allocation plans, and market expansion roadmaps with confidence.

    Frequently asked questions

    What is the current size of France's veterinary biologics market?

    France's veterinary biologics market is valued at USD 71.19 million in 2025 and is expected to reach USD 95.48 million by 2030.

    What is the projected growth rate for France's veterinary biologics market?

    France's veterinary biologics market is projected to grow at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2030.

    What factors are driving growth in France's veterinary biologics market?

    Growth in France's veterinary biologics market is driven by rising pet ownership, increased livestock disease management needs, growing awareness of preventive healthcare, and France's strong agricultural sector.

    How does France's regulatory environment support the veterinary biologics market?

    France benefits from EU regulatory harmonization, which ensures stringent quality controls, streamlined market access, and standardized approval processes for veterinary biologics across the country.

    Which segments are most significant in France's veterinary biologics market?

    France's veterinary biologics market encompasses both companion animal and production animal segments, with vaccines, immunological products, and therapeutic biologics representing key product categories.

    RESEARCH METHODOLOGY

    This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

    Secondary Research

    This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

    A breakdown of the primary respondents is provided below:

    Veterinary Biologics Market

    Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

    Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Source: MarketsandMarkets Analysis

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

    Veterinary Biologics Market

    Data Triangulation

    After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

    Market Definition

    The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

    Stakeholders

    • Veterinary Biologics Manufacturers
    • Animal Healthcare Product Manufacturers
    • Veterinary Biologics Distributors and Wholesalers
    • Animal Welfare Associations
    • Veterinary Clinics and Care Centers
    • Research And Consulting Firms
    • Veterinary Research and Development Organizations
    • Contract Manufacturing Organizations
    • Venture Capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
    • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

     

    Get the Full Veterinary Biologics Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status